Researchers Studying Oral Medicine to Treat Medulloblastoma, High-Grade Glioma, DIPG Brain Tumors and Other Brain Tumor Types
Phase: Recruiting
First Posted: January
Condition(s): Medulloblastoma, High-Grade Glioma, DIPG Brain Tumors, Other Brain Tumor Types
NCT Number: NCT03598244 Other Study ID Number(s): PBTC-049
What Is the Purpose of This Study?
To study an oral drug to see if it is an effective treatment for recurrent or refractory primary CNS brain tumors in children.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Have confirmed medulloblastoma, high-grade glioma, DIPG brain tumors, and other brain tumor types with a specific genetic marker, which continue to grow or have come back after the prior treatment.
- Are 6-21 years old.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT03598244
What Will Happen During This Study?
- Patients will take the medication one time daily for 28 days in a row. This is considered one course.
- Treatment may continue for 39 courses (3 years).
Principal Investigator
Discover More Research
Explore additional studies relating to neuro-oncologyYour Might Also Be Interested In
Neuro-Oncology
Our highly experienced and internationally recognized team of pediatric neuro-oncologists, neurosurgeons and neuroradiologists will care for your child by providing the most advanced and innovative treatments, while at the same time, paying careful attention to all the needs and concerns of your child and family.
Medulloblastoma
Medulloblastomas are tumors that develop in the brain, most commonly in a region called the cerebellum. The cerebellum is located next to the brainstem and controls coordination, balance and other motor skills.
Brain Tumors
Brain tumors are the most common solid tumors in children. Primary brain tumors start in the brain and usually do not spread outside the brain tissue.